Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study

Translational Psychiatry(2021)10.1038/s41398-021-01602-5Source: DataRank Database

Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study is a research paper published in Translational Psychiatry (2021). On theSindex it has a DataRank of 0.637. It has been cited 69 times.

N/A

0.637DataRank · unranked

Scored on demand from live citation data

Open Access69 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 5.46)OA: goldTopics (121)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.637

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (99)

Jiaying Lu ORCID,Hong‐Qi Li,Yuxiang Yang ORCID,Jiehui Jiang ORCID,Mei Cui ORCID

Live enrichment

PubMed:34537810 PMC:PMC8449785 OpenAlex:https://openalex.org/W3201026716

NIA NIH HHS

Grant: P30 AG066512

NIA NIH HHS

Grant: U01 AG024904

NCATS NIH HHS

Grant: UL1 TR001422

National Institutes of Health

Grant: 1U01AG024904-01

Alzheimers Disease Neuroimaging Initiative

Canadian Institutes of Health Research

Grant: unidentified

unidentified

CIHR

FWCI

5.46

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.nature.com/articles/s41398-021-01602-5.pdf

publisherhttps://www.nature.com/articles/s41398-021-01602-5.pdf

publisherhttps://www.nature.com/articles/s41398-021-01602-5

journalhttps://doi.org/10.1038/s41398-021-01602-5

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34537810

Fields of Study

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeurological Disease Mechanisms and Treatments0302 clinical medicine03 medical and health sciencesAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersCognitive DysfunctionFemaleHumansLongitudinal StudiesMalePositron-Emission Tomographytau Proteins

MeSH Terms

AgedAged, 80 and overAlzheimer DiseaseFemaleHumansLongitudinal StudiesMaleBiomarkersAmyloid beta-Peptidestau ProteinsPositron-Emission TomographyCognitive Dysfunction

Keywords

BiomarkerStage (stratigraphy)Alzheimer's Disease Neuroimaging InitiativeCognitive declineOncologyDiseaseHazard ratioPsychologyProportional hazards modelNeuroimagingPositron emission tomographyInternal medicineCognitionAlzheimer's diseaseAmyloid (mycology)NeuropathologyMedicineDementiaNeurosciencePathologyBiologyConfidence intervalMaleAging1117 Public Health and Health Services (for)Biological PsychologyNeurodegenerativeAcquired Cognitive Impairment (rcdc)Clinical Research (rcdc)Aging (rcdc)Biomedical Imaging (rcdc)Brain Disorders (rcdc)Amyloid beta-Peptides (mesh)Cognitive Dysfunction (mesh)1103 Clinical Sciences (for)Dementia (rcdc)80 and over (mesh)80 and over2.1 Biological and endogenous factorsLongitudinal Studies32 Biomedical and Clinical Sciences (for-2020)Male (mesh)Neurosciences (rcdc)Neurodegenerative (rcdc)Alzheimer Disease (mesh)Aged, 80 and overHumans (mesh)Alzheimer's Disease (rcdc)52 Psychology (for-2020)3209 Neurosciences (for-2020)Biomarkers (mesh)4.2 Evaluation of markers and technologies (hrcs-rac)NeurologicalPublic Health and Health Services5202 Biological Psychology (for-2020)Biomedical ImagingFemale4.2 Evaluation of markers and technologiesRC321-571Clinical SciencesPositron-Emission Tomography (mesh)610Neurosciences. Biological psychiatry. Neuropsychiatrytau ProteinsArticleClinical ResearchAlzheimer Disease616Acquired Cognitive ImpairmentHumansCognitive Dysfunction3202 Clinical Sciences (for-2020)AgedAmyloid beta-PeptidesBiomedical and Clinical SciencesNeurological (hrcs-hc)Aged (mesh)4.1 Discovery and preclinical testing of markers and technologies (hrcs-rac)NeurosciencesAlzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)2.1 Biological and endogenous factors (hrcs-rac)Alzheimer’s Disease Neuroimaging InitiativeLongitudinal Studies (mesh)Brain Disorders4.1 Discovery and preclinical testing of markers and technologiesFemale (mesh)Positron-Emission TomographyMedical BiophysicsAlzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) (rcdc)1701 Psychology (for)tau Proteins (mesh)Biomarkers

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being